Lung Non-Squamous Non-Small Cell Cancer

EA5163/S1709/INSIGNA, led by @HosseinBorghaei of @FoxChaseCancer and @Annechiangmd of @YaleCancer, is a randomized phase III study treating patients w/ stage IV non-squamous non-small cell lung cancer. More: https://t.co/lytPoY6qjZ #lcsm #nsclc cc: @lcrf_org, @GO2forLungCancr (@eaonc)

Abstract LBA9000: Pemetrexed and platinum +/- pembrolizumab for TKI-resistant, EGFR-mutant, metastatic nonsquamous NSCLC (KEYNOTE-789) by James CH Yang. Well-powered but "MARGINALLY" negative like CheckMate 722. No durable response even in ICI responders. #ASCO23 #LCSM (@HHorinouchi)

EA5163/S1709/INSIGNA, led by @HosseinBorghaei of @FoxChaseCancer and @Annechiangmd of @YaleCancer, is a randomized phase III study treating patients w/ stage IV non-squamous non-small cell lung cancer. More: https://t.co/lytPoY6qjZ #lcsm #nsclc cc: @lcrf_org, @GO2forLungCancr (@eaonc)

AVM: CHOICE-01 toripalimab (PD1) vs. placebo in combination chemotherapy in NSCLC adds to multiple trials showing known benefit of ICIs OS HR 0.73 Non-squamous subgroup w/ better outcomes OS HR 0.50, median OS 27.8 vs 15.9 mo #LCSM #ASCO23 @AnaVManana (@OncLive)

AVM: SCARLET Study WJOG14821L Single arm Ph2 sotorasib + chemo in KRAS G12c nonsquamous mNSCLC 🔹N=30, chemo & KRAS inhibitor naive 🔹1ry endpoint ORR: 88.9% No diff in ORR by PD-L1 expression mPFS and mOS NR but limited f/u at analysis of only 4 mo #LCSM #ASCO23 @AnaVManana (@OncLive)

TPS9149: Phase 2 Study of Telisotuzumab Vedotin (Teliso-V) Monotherapy in Patients With Previously Untreated MET Amplified Locally Advanced/Metastatic Non-squamous Non-small Cell Lung Cancer (NSQ NSCLC). MET-specialist ADC for MET Amp. #ASCO23 #LCSM (@HHorinouchi)

EA5163/S1709/INSIGNA, led by @HosseinBorghaei of @FoxChaseCancer and @Annechiangmd of @YaleCancer, is a randomized phase III study treating patients w/ stage IV non-squamous non-small cell lung cancer. More: https://t.co/lytPoY6qjZ #lcsm #nsclc cc: @lcrf_org, @GO2forLungCancr (@eaonc)

Thrilled to share our multi-center collaborative work! Nonsquamous NSCLCs with high aneuploidy and chromosome 9p loss have a distinct tumor immune microenvironment and less favorable responses to ICIs. @alessi_joao @ArielleElkrief @BiagioRicciutMD @AdamJSchoenfeld @DrMarkAwad (@XinAnnWang)

4/ #ASCO23 Abs9006 #LCSM 💡SCARLET: ✅ Sotorasib + platinum-doublet chemo shows promising results in chemo-naive, adv non-squamous NSCLC pts w/ KRAS G12C mutation (jRCT2051210086). 🔥 ORR: 88.9%, 6-mo PFS: 61.2%, 6-mo OS: 87%. ⚠️ AE: Mostly manageable hematological toxicities.… https://t.co/xTQFTNwxbf (@ADesaiMD)

Combined use of tusamitamab ravtansine with SoC therapy showed promising anti-tumour activity with a favourable safety profile for patients with nonsquamous NSCLC. Watch Dr Luis Paz-Ares discuss his study 👉https://t.co/TIEPrncYSA #ELCC2023 @LuisPaz_Ares @unicomplutense (@ecancer)

EA5163/S1709/INSIGNA, led by @HosseinBorghaei of @FoxChaseCancer and @Annechiangmd of @YaleCancer, is a randomized phase III study treating patients w/ stage IV non-squamous non-small cell lung cancer. More: https://t.co/lytPoY6qjZ #lcsm #nsclc cc: @lcrf_org, @GO2forLungCancr (@eaonc)

MET-specialist ADC in MET amplification: Preliminary Efficacy of Telisotuzumab Vedotin Treatment in the 2L/3L Setting in MET Gene Amplified, c-Met Protein Overexpressing, Non-squamous, NSCLC: Retrospective Analysis of LUMINOSITY by Dr. Ross Camidge. #AACR23 #LCSM (@HHorinouchi)

#ASCO23 TPS9149: Phase 2 study of telisotuzumab vedotin (Teliso-V) monotherapy in pts with previously untreated MET-amplified locally advanced/metastatic non-squamous non-small cell lung cancer. Check a MET-specialist ADC. See you @McCormick_Place @ASCO https://t.co/JnTtA9xH0Q (@HHorinouchi)

For patients with NSCLC treated with mono or dual ICI, PD-L1 expression was more predictive of benefit for non-squamous than squamous. https://t.co/MfWYwpDglL (@MLPOncoData)

Dear Twittersphere, anyone know if Braf Val600_Lys601 delinsGlu is sensitive to targeted options in NS-NSCLC? Looks like a nasty frameshift mutation. Open to opinions 🙏 (@NormandBlais)

😳😳😳 🇯🇵 ORR 90.9%, mPFS 31.0 months, and mOS not reached. Phase 2 Study of Osimertinib in Combination with Platinum and Pemetrexed in Patients with Previously Untreated EGFR-Mutated Advanced Non-Squamous Non-Small Cell Lung Cancer: The OPAL Study. #LCSM https://t.co/Xo2RCIdZfw (@Tony_Calles)

KEYNOTE-789: Pembro +chemo vs. chemo for TKI-resistant, EGFR-mutated metastatic, non-squamous NSCLC (n=492)--> No statistically significant improvement in PFS and OS with Pembro. https://t.co/ofo70EzvVx (@dipeshuprety4)

Merck Provides Update on Phase 3 Trials KEYNOTE-641 and KEYNOTE-789 KN-641➡️mCRPC, Enza+ADT+Pembro Result: Primary endpoints not meet❗ KN-789➡️EGFR mt+, nsNSCLC, post-TKI, ChT plus Pembo Result: Primary endpoints not meet❗ @OncoAlert https://t.co/l4SJM12Lfp (@dr_yakupergun)

KEYNOTE-189 : 5-year outcomes: The longest follow-up of a combo of IO + chemo as 1st line for NS-NSCLC. Pembro + pem-platinum continued to demonstrate prolonged OS regardless of PDL1 expression Very proud to participate in this trial. @Hospital_FJD @UAM_Madrid @OncoAlert @AEACaP (@ManuelDomine)

Findings from the phase 2 TELMA trial suggest that atezolizumab plus bevacizumab yields robust, long-lasting outcomes for patients with metastatic nonsquamous tumor mutational burden–high non–small cell lung cancer. #NSCLC | @MARIANOPROVENCI https://t.co/09eQuF1gTL (@CancerNetwrk)

Tusamitamab Ravtansine Is Under Investigation in CEACAM5+ Nonsquamous NSCLC #lcsm #Oncology https://t.co/vcMpvjRmPj (@OncLive)

1L #Atezolizumab #Immunotherapy + Bevacizumab in Metastatic Nonsquamous #NSCLC With High Tumor Mutation Burden, a small study reported activity, #chemotherapy free regimen - The #ASCO Post https://t.co/lguP29kcI0 (@Jaskirat__SR)

🚨‼️#ECOG #ACRIN #EA5163 Important phase 3 randomized #ClinicalTrial ENROLLING NOW at several centers including @MayoCancerCare comparing standard of care treatment options for patients with advanced #NSCLC (non-squamous) with PD-L1 of ≥ 1% in 1st line & beyond. @HosseinBorghaei https://t.co/ky7fogyPuO (@RManochakian)

The addition of bevacizumab to atezolizumab in the frontline setting showed promising efficacy among patients with nonsquamous non-small cell lung cancer with high tumor mutational burden. https://t.co/vOEEBkwlSh #OncoTwitter @JPatelMD #LungCancer (@JWatch)

.@AlexSpiraMDPhD discusses targeting CEACAM5 in NSCLC, how tusamitamab ravtansine could provide encouraging frontline responses in the CEACAM5-positive, nonsquamous population, and enrollment challenges faced by ongoing clinical trials. #lcsm #oncology https://t.co/BwT4GseHwA (@OncLive)

Targeting CEACAM5 with the ADC tusamitamab ravtansine may improve treatment outcomes in patients with CEACAM5-positive, nonsquamous NSCLC @AlexSpiraMDPhD #lcsm #oncology https://t.co/KADX4AYlbk (@OncLive)

Anti-CEACAM5 ADC Could Represent the Next Targeted Therapy in Advanced Nonsquamous NSCLC #lcsm @AlexSpiraMDPhD @VCSpecialists https://t.co/K8hSDmSRyC (@OncLive)

Atezolizumab Plus Bevacizumab for Nonsquamous NSCLC With High Tumor Mutation Burden https://t.co/geA9gX2zB2 vía @JAMAOnc part of @JAMANetwork (@MARIANOPROVENCI)

TELMA: a trial from @gecp_org using Atezo + BVZ as 1st-line treatment in metastatic nonsquamous NSCLC with high TMB. A very effective and tolerable regimen without chemotherapy. Just published JAMA Oncology @Hospital_FJD @DocenciaFJD @UAM_Madrid @OncoAlert @myESMO #LCSM @AEACaP (@ManuelDomine)

Orgulloso de mis compañeros oncólogos del @gecp_org La fuerza de la colaboración @MARIANOPROVENCI @bmassutis @analauraortega Atezolizumab Plus Bevacizumab for Nonsquamous NSCLC With High Tumor Mutation Burden https://t.co/dnTe03eqmM a través de @JAMAOnc part of @JAMANetwork (@albertoruano8)

A New GECP study!!! Atezolizumab Plus Bevacizumab for Nonsquamous NSCLC With High Tumor Mutation Burden https://t.co/j6RZ9NXe7T a través de @JAMAOnc part of @JAMANetwork (@MARIANOPROVENCI)

Update from POSEIDON (1L durvalumab + tremelimumab + chemotherapy) for NSCLC by Dr. Byoung Chul Cho at #ESMOAsia22. Median f/u 46m and OS benefit seen with addition of durva + treme persists (OS HR 0.75 vs chemo) including in STK11 mutant non-squamous subset. (@StephenVLiu)

Results from CHOICE-01 trial @JCO_ASCO: phase III trial shows addition of anti-PD1 toripalimab to 1L chemo for NSCLC improves PFS (HR 0.49) across PDL1 strata. OS benefit (HR 0.69), but driven by nonsquamous (HR 0.48, n-245), not squamous (HR 0.99, n=220). https://t.co/Ihve4oBTMW (@StephenVLiu)

🚨‼️ #ECOG #ACRIN #EA5163 Important phase 3 randomized #ClinicalTrial ENROLLING NOW at several centers including @MayoCancerCare comparing two standard of care treatment options for patients with advanced #NSCLC (non-squamous) with PD-L1 of ≥ 1%. @HosseinBorghaei @eaonc https://t.co/IjWM88uMb5 (@RManochakian)

👍🏻 to @marinagarassino on #KEYNOTE189 5y update: 1L pbo+pem-platinum vs pbo+pem-platinum continued to show improvement in OS (mOS: 22.0mo vs 10.6mo; 5-yOS: 19.4% vs 11.3%) and PFS benefits (9.0mo vs 4.9mo), irrespective of PD-L1 expression in metastatic nonsquamous NSCLC. #ESMO22 (@wearemedsir)

#Ex20ins. NGS using up to date technology should be done in every new patient with non-squamous advanced stage NSCLC , but EGFR ex20ins is just small piece of the puzzle. In no way the main justification. And don’t forget the issue of up to date technology: a fast moving field (@drgandara)

#ELCC22 Here, we see subsets within the PD-L1 ≥ 50% group. Greatest benefit in node positive NSCLC and outcomes somewhat better in non-squamous set. No new safety signals appreciated. As expected, more immunotherapy delivered post-relapse in the control arm. (@StephenVLiu)

Retrospective comparison of chemo-IO vs IO alone in non-squamous, PDL1 high NSCLC @Annals_Oncology showed no difference in PFS/OS. Selection bias makes comparison hard but interesting data. Await INSIGNA. Of note, never smokers fared better with chemoIO. https://t.co/yAMaPuvqbx (@StephenVLiu)

Single arm phase II study of 1L atezolizumab + bevacizumab for PDL1 high non-squamous NSCLC led by Dr. @TakashiSeto3 now @jitcancer. In 39pts, RR 64%, mDOR 10.4m. Anti-VEGF continues to be interesting but still need to develop the optimal strategy for use. https://t.co/XjDuhNFxot (@StephenVLiu)

Phase II study of atezolizumab with bevacizumab for non-squamous non-small cell lung cancer with high PD-L1 expression (@Be Study) | Journal for ImmunoTherapy of Cancer https://t.co/iUceXrvjnB (@VivekSubbiah)

#ESMOasiaweek21: Encouraging results w/ sintilimab combo therapy in EGFR-mutated non-squamous #NSCLC. In the first interim analysis of the ORIENT-31 trial, PFS was slightly improved in pts who progressed after EGFR TKI. ➡️ https://t.co/ivK4PMfxKj #lcsm #lungcancer @APassaroMD (@myESMO)

In a poster presentation at #SITC21, @DrRoyHerbstYale reports on "KRAS Mutations in Patients with Non-squamous #NSCLC: Prevalence and Relationship with PD-L1 Expression, Tumor Mutation Burden and Smoking Status." @SmilowCancer @YaleMed @YNHH @sitcancer #lcsm (@YaleCancer)